Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up-Reference-Cited by-同舟云学术

Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up

Published:2014-02-05 Issue:1 Volume:33 Page:1-8
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematol Oncol

Author:

Nicolas-Virelizier Emmanuelle¹,Ségura-Ferlay Céline²,Ghesquières Herve¹,Chassagne-Clément Catherine³,Gargi Thérèse²,Biron Pierre¹,Belhabri Amine¹,Rey Philippe¹,Faurie Pierre¹,Chabaud Sylvie²,Sebban Catherine¹

Affiliation:

1. Hematology Department; Centre Leon Berard; Lyon France

2. Biostatistics Unit; Centre Leon Berard; Lyon France

3. Histopathology Department; Centre Leon Berard; Lyon France

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Reference27 articles.

1. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's lymphoma classification project;Armitage;J Clin Oncol,1998

2. Follicular lymphoma international prognostic index;Solal-Céligny;Blood,2004

3. New treatment options have changed the survival of patients with follicular lymphoma;Fisher;J Clin Oncol,2005

4. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma;Marcus;J Clin Oncol,2008

5. Frontline therapy with Rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group;Hiddemann;Blood,2005

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rituximab Improves the Outcome of Patients With Grade 3 Follicular Lymphoma Receiving Anthracycline-Based Therapy;Clinical Lymphoma Myeloma and Leukemia;2017-08

2. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma;American Journal of Hematology;2016-09-03

3. Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database;Leukemia & Lymphoma;2015-10-12